Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Clinical trial NCT04490993 · UNKNOWN
Trial details
- NCT number
- NCT04490993
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-30
- Primary completion
- 2022-05-30
- Enrollment
- 359
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.